Literature DB >> 18612276

Commercial interest waxes for IGF-1 blockers.

Randy Osborne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18612276     DOI： 10.1038/nbt0708-719

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2012-10       Impact factor: 54.908

2.  Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

Authors:  Meizhong Jin; Prafulla C Gokhale; Andy Cooke; Kenneth Foreman; Elizabeth Buck; Earl W May; Lixin Feng; Mark A Bittner; Mridula Kadalbajoo; Darla Landfair; Kam W Siu; Kathryn M Stolz; Douglas S Werner; Radoslaw S Laufer; An-Hu Li; Hanqing Dong; Arno G Steinig; Andrew Kleinberg; Yan Yao; Jonathan A Pachter; Robert Wild; Mark J Mulvihill
Journal:  ACS Med Chem Lett       Date:  2010-08-30       Impact factor: 4.345

Review 3.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

4.  Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

Authors:  Dedra H Fagan; Ryan R Uselman; Deepali Sachdev; Douglas Yee
Journal:  Cancer Res       Date:  2012-05-09       Impact factor: 12.701

Review 5.  Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

Authors:  Dedra H Fagan; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-12       Impact factor: 2.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.